HQY vs. GMED, ENSG, ACHC, EXEL, ITCI, PCVX, JAZZ, ELAN, MASI, and CYTK
Should you be buying HealthEquity stock or one of its competitors? The main competitors of HealthEquity include Globus Medical (GMED), The Ensign Group (ENSG), Acadia Healthcare (ACHC), Exelixis (EXEL), Intra-Cellular Therapies (ITCI), Vaxcyte (PCVX), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Masimo (MASI), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
Globus Medical (NYSE:GMED) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Globus Medical has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
In the previous week, Globus Medical had 4 more articles in the media than HealthEquity. MarketBeat recorded 6 mentions for Globus Medical and 2 mentions for HealthEquity. HealthEquity's average media sentiment score of 0.94 beat Globus Medical's score of 0.45 indicating that Globus Medical is being referred to more favorably in the media.
Globus Medical received 31 more outperform votes than HealthEquity when rated by MarketBeat users. However, 69.24% of users gave HealthEquity an outperform vote while only 67.83% of users gave Globus Medical an outperform vote.
95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 24.3% of Globus Medical shares are owned by insiders. Comparatively, 2.7% of HealthEquity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Globus Medical presently has a consensus price target of $66.33, indicating a potential upside of 31.41%. HealthEquity has a consensus price target of $96.17, indicating a potential upside of 20.59%. Given HealthEquity's higher probable upside, analysts clearly believe Globus Medical is more favorable than HealthEquity.
Globus Medical has a net margin of 7.83% compared to Globus Medical's net margin of 5.57%. HealthEquity's return on equity of 8.82% beat Globus Medical's return on equity.
Globus Medical has higher revenue and earnings than HealthEquity. Globus Medical is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
Summary
Globus Medical beats HealthEquity on 12 of the 18 factors compared between the two stocks.
Get HealthEquity News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HealthEquity Competitors List
Related Companies and Tools
